1644 A

PTO/SB/21 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Application Number** 

# **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10/051,497-Conf. #1774 Filing Date January 18, 2002 First Named Inventor Rong-Hwa Lin Art Unit 1644 **Examiner Name** P. Gambel Attorney Docket Number A0871.70000US01

ENCLOSURES (Check all that apply)							
X Fee Trans	mittal Form	Drawing(s)	After Allowance Communication to TC				
X Fee	Attached (check for \$180)	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendme	nt/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After	Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affid	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter				
Extension	of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):				
Express A	bandonment Request	Request for Refund	Form PTO 1449 Copy of 1.16.2007 Office Action in				
x Information	n Disclosure Statement	CD, Number of CD(s)	Japanese Application No. 2003- 518607				
Certified C Document	opy of Priority (s)	Landscape Table on CD	1 copy each of 2 references Return Receipt Postcard				
	lissing Parts/ Application	Remarks	<del></del>				
	y to Missing Parts under FR 1.52 or 1.53						
		•					
	SIGNATI	JRE OF APPLICANT, ATTORNEY, O	RAGENT				
Firm Name	WOLF, GREENFIELD & SACKS, P.C.						
Signature							
Printed name	Alan W. Steele, M.D., Ph.D.						
Date	March 15, 2007	Reg. No.	45,128				

18

_				
l		g with any paper referre		enclosed) is being deposited with the U.S. Postal Service on
l	the date shown below with sufficien Patents, P.O. Box 1450, Alexandria		s Mail in an envelope addre	essed to: Mail Stop Amendment, Commissioner for
١	Dated: March 15, 2007	Signature: _	W.	(Alan W. Steele, M.D., Ph.D.)

MAR 19 2007 8

PTO/SB/17 (07-06) Approved for use through 01/31/2007. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Effective on 12/08/2004. 10/051,497-Conf. #1774 es pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). Application Number TRANSMIT January 18, 2002 Filing Date Rong-Hwa Lin First Named Inventor For FY 2006 **Examiner Name** P. Gambel Applicant claims small entity status. See 37 CFR 1.27 1644 Art Unit Attorney Docket No. A0871.70000US01 TOTAL AMOUNT OF PAYMENT (\$) 180.00 METHOD OF PAYMENT (check all that apply) Credit Card Money Order None Other (please identify): x Check Wolf, Greenfield & Sacks, P.C. Deposit Account Deposit Account Number: 23/2825 Deposit Account Name: For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 x Credit any overpayments **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES Small Entity Small Entity** Small Entity **Application Type** Fee (\$) Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Utility 300 150 500 250 200 100 130 65 200 100 100 50 Design 200 300 150 160 80 Plant 100 500 250 600 300 Reissue 300 150 Provisional 200 100 0 0 0 0 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) **Fee Description** Each claim over 20 (including Reissues) 50 25 Each independent claim over 3 (including Reissues) 200 100 Multiple dependent claims 360 180 **Multiple Dependent Claims Total Claims** Fee Paid (\$) Extra Claims - 37 = Fee (\$) Fee Paid (\$) HP = highest number of total claims paid for, if greater than 20. Indep. Claims Extra Claims Fee Paid (\$) 4 X HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Number of each additional 50 or fraction thereof Fee Paid (\$) Extra Sheets (round up to a whole number) x - 100 = 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00 SUBMITTED BY Registration No. 45,128 Telephone (617) 646-8000 Signature (Attorney/Agent) Name (Print/Type) Alan W. Steele, M.D., Ph.D. March 15, 2007

	Certificate of Mailin	g Under 37 CFR 1.8(a)
		attached or enclosed) is being deposited with the U.S. Postal Service on
		nvelope addressed to: MAIL STOP AMENDMENT, Commissioner for
Patents, P.O. Box 1450, Alexandria, VA	22313-1450.	
Dated: March 15, 2007	Signature: W	(Alan W. Steele, M.D., Ph.D.)
Dated: March 13, 2007	Signature.	(Alah VV. Steele, W.D., Fil.D.)

MAR 1 9 2007 BDOCKET NO.: A0871.70000US01

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rong-Hwa Lin et al.

Serial No.:

10/051497

Confirmation No.:

1774

Filed:

January 18, 2002

For:

METHODS OF MODULATING T-CELL OR NATURAL KILLER CELL ACTIVITY WITH ANTI-P-SELECTIN

**GLYCOPROTEIN LIGAND 1 ANTIBODIES** 

Examiner:

Phillip Gambel

Art Unit:

1644

#### **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 15th day of March, 2007.

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUPPLEMENTAL STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

#### PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first of Free actions but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

Serial No.: 10/051497 -2 - Art Unit: 1644

Conf. No.: 1774

## PART II: Compliance with 37 C.F.R. §1.704(d)

Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by the office of the undersigned more than thirty (30) days prior to the filing of this Information Disclosure Statement.

#### PART III: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the enclosed English translation of an office action from corresponding Japanese Application No. 2003-518607 dated January 16, 2007.

Japanese Application No. 2005-503756 (in Japanese), cited in the office action from corresponding Japanese Application No. 2003-518607 dated January 16, 2007, is the national phase application of WO 02/053700 A2 (in English), the latter of which is submitted herewith.

#### PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

Serial No.: 10/051497 - 3 - Art Unit: 1644

Conf. No.: 1774

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

Alan W. Steele, M.D., Ph.D.

Reg. No. 45,128

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: A0871.70000US01

Date: March 15, 2007

x03/21/07x

	MAR 1.9 7007					
EODW BIX	Å	odifia	1 PTO/SR/08)	APPLICATION NO.:	10/051497	ATTY. DOCKET NO.: A0871.70000US01
FORM PTO 2449/A and Burnodified PTO/SB/08)  INFORMATION DISCLOSURE  STATEMENT BY APPLICANT			FILING DATE:	January 18, 2002	CONFIRMATION NO.: 1774	
			APPLICANT:	Rong-Hwa Lin et a	al.	
Sheet	1	of	1	GROUP ART UNIT:	1644	EXAMINER: Phillip Gambel
L	<u> </u>		<u> </u>			

#### U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Docu	ment	Name of Patentee or Applicant of Cited	Date of Publication or Issue	
Initials #	No.	Number	Kind Code	Dogument Of Cited Bo	of Cited Document MM-DD-YYYY	
			<del>                                     </del>			
-						

#### FOREIGN PATENT DOCUMENTS

Examiner's	Cite	For	eign Patent Docu	ment	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)
		JP	09-227410	Α	Sumitomo Pharmaceut Co. Ltd.	09-02-1997	in part
		WO	02/053700	A2	Bio-Technology General Corp.	07-11-2002	
	<u> </u>			<del> </del>			

### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	t		

EXAMINER:	DATE CONSIDERED:

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

<sup>#</sup> EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>\*</sup>a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).